Liquid Biopsy May Guide EGFR Inhibitor Treatment.

Abstract

A liquid biopsy may select patients with metastatic colorectal cancer who are good candidates for additional anti-EGFR therapy after developing resistance to it earlier in their treatment regimen. In a phase II trial, patients who received panitumumab based on an absence of resistance mutations in circulating tumor DNA had a 30% response rate to the anti-EGFR agent.